Serial prostate specific antigen screening for prostate cancer: A computer model evaluates competing strategies

Ruth Etzioni, Raymond Cha, Mark E. Cowen

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: We compare prostate specific antigen (PSA) screening strategies in terms of expected years of life saved with screening, number of screens, number of false-positive screens and rates of over diagnosis, defined as detection by PSA screening of patients who would never have been diagnosed without screening. Materials and Methods: A computer model of disease progression, clinical diagnosis, PSA growth and PSA screening was used. Under baseline conditions, when screening is not considered, the model replicates clinical diagnosis and disease mortality rates recorded by the Surveillance, Epidemiology and End Results Program of the National Cancer Institute in the mid 1980s. Results: Biannual screening with PSA greater than 4.0 ng./ml, was projected to reduce the number of screens and false-positive tests by almost 50% relative to annual screening while retaining 93% of years of life saved. With annual screening use of an age specific bound for PSA to consider a test positive instead of the standard 4.0 ng./ml. was projected to reduce false- positive screens by 27% and over diagnosis by a third while retaining almost 95% of years of life saved. Sensitivity analyses did not change the relative efficacy of biannual screening. Conclusions: Under the model assumptions biannual PSA screening is a cost-effective alternative to annual PSA screening for prostate cancer. With annual screening use of an age specific bound for PSA positivity appears to reduce false-positive results and over diagnosis rates sharply relative to a bound of 4 ng./ml, while retaining most of the survival benefits.

Original languageEnglish (US)
Pages (from-to)741-748
Number of pages8
JournalJournal of Urology
Volume162
Issue number3 I
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Computer Simulation
Prostatic Neoplasms
SEER Program
National Cancer Institute (U.S.)
Disease Progression
Costs and Cost Analysis
Survival
Mortality
Growth

Keywords

  • Computer simulation
  • Cost-benefit analysis
  • Mass screening
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Urology

Cite this

Serial prostate specific antigen screening for prostate cancer : A computer model evaluates competing strategies. / Etzioni, Ruth; Cha, Raymond; Cowen, Mark E.

In: Journal of Urology, Vol. 162, No. 3 I, 01.01.1999, p. 741-748.

Research output: Contribution to journalArticle

Etzioni, Ruth ; Cha, Raymond ; Cowen, Mark E. / Serial prostate specific antigen screening for prostate cancer : A computer model evaluates competing strategies. In: Journal of Urology. 1999 ; Vol. 162, No. 3 I. pp. 741-748.
@article{888a4e96af7d425bbca89088a3b5be55,
title = "Serial prostate specific antigen screening for prostate cancer: A computer model evaluates competing strategies",
abstract = "Purpose: We compare prostate specific antigen (PSA) screening strategies in terms of expected years of life saved with screening, number of screens, number of false-positive screens and rates of over diagnosis, defined as detection by PSA screening of patients who would never have been diagnosed without screening. Materials and Methods: A computer model of disease progression, clinical diagnosis, PSA growth and PSA screening was used. Under baseline conditions, when screening is not considered, the model replicates clinical diagnosis and disease mortality rates recorded by the Surveillance, Epidemiology and End Results Program of the National Cancer Institute in the mid 1980s. Results: Biannual screening with PSA greater than 4.0 ng./ml, was projected to reduce the number of screens and false-positive tests by almost 50{\%} relative to annual screening while retaining 93{\%} of years of life saved. With annual screening use of an age specific bound for PSA to consider a test positive instead of the standard 4.0 ng./ml. was projected to reduce false- positive screens by 27{\%} and over diagnosis by a third while retaining almost 95{\%} of years of life saved. Sensitivity analyses did not change the relative efficacy of biannual screening. Conclusions: Under the model assumptions biannual PSA screening is a cost-effective alternative to annual PSA screening for prostate cancer. With annual screening use of an age specific bound for PSA positivity appears to reduce false-positive results and over diagnosis rates sharply relative to a bound of 4 ng./ml, while retaining most of the survival benefits.",
keywords = "Computer simulation, Cost-benefit analysis, Mass screening, Prostate-specific antigen",
author = "Ruth Etzioni and Raymond Cha and Cowen, {Mark E.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1097/00005392-199909010-00032",
language = "English (US)",
volume = "162",
pages = "741--748",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3 I",

}

TY - JOUR

T1 - Serial prostate specific antigen screening for prostate cancer

T2 - A computer model evaluates competing strategies

AU - Etzioni, Ruth

AU - Cha, Raymond

AU - Cowen, Mark E.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Purpose: We compare prostate specific antigen (PSA) screening strategies in terms of expected years of life saved with screening, number of screens, number of false-positive screens and rates of over diagnosis, defined as detection by PSA screening of patients who would never have been diagnosed without screening. Materials and Methods: A computer model of disease progression, clinical diagnosis, PSA growth and PSA screening was used. Under baseline conditions, when screening is not considered, the model replicates clinical diagnosis and disease mortality rates recorded by the Surveillance, Epidemiology and End Results Program of the National Cancer Institute in the mid 1980s. Results: Biannual screening with PSA greater than 4.0 ng./ml, was projected to reduce the number of screens and false-positive tests by almost 50% relative to annual screening while retaining 93% of years of life saved. With annual screening use of an age specific bound for PSA to consider a test positive instead of the standard 4.0 ng./ml. was projected to reduce false- positive screens by 27% and over diagnosis by a third while retaining almost 95% of years of life saved. Sensitivity analyses did not change the relative efficacy of biannual screening. Conclusions: Under the model assumptions biannual PSA screening is a cost-effective alternative to annual PSA screening for prostate cancer. With annual screening use of an age specific bound for PSA positivity appears to reduce false-positive results and over diagnosis rates sharply relative to a bound of 4 ng./ml, while retaining most of the survival benefits.

AB - Purpose: We compare prostate specific antigen (PSA) screening strategies in terms of expected years of life saved with screening, number of screens, number of false-positive screens and rates of over diagnosis, defined as detection by PSA screening of patients who would never have been diagnosed without screening. Materials and Methods: A computer model of disease progression, clinical diagnosis, PSA growth and PSA screening was used. Under baseline conditions, when screening is not considered, the model replicates clinical diagnosis and disease mortality rates recorded by the Surveillance, Epidemiology and End Results Program of the National Cancer Institute in the mid 1980s. Results: Biannual screening with PSA greater than 4.0 ng./ml, was projected to reduce the number of screens and false-positive tests by almost 50% relative to annual screening while retaining 93% of years of life saved. With annual screening use of an age specific bound for PSA to consider a test positive instead of the standard 4.0 ng./ml. was projected to reduce false- positive screens by 27% and over diagnosis by a third while retaining almost 95% of years of life saved. Sensitivity analyses did not change the relative efficacy of biannual screening. Conclusions: Under the model assumptions biannual PSA screening is a cost-effective alternative to annual PSA screening for prostate cancer. With annual screening use of an age specific bound for PSA positivity appears to reduce false-positive results and over diagnosis rates sharply relative to a bound of 4 ng./ml, while retaining most of the survival benefits.

KW - Computer simulation

KW - Cost-benefit analysis

KW - Mass screening

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=0032833235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032833235&partnerID=8YFLogxK

U2 - 10.1097/00005392-199909010-00032

DO - 10.1097/00005392-199909010-00032

M3 - Article

C2 - 10458357

AN - SCOPUS:0032833235

VL - 162

SP - 741

EP - 748

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3 I

ER -